Citius Pharmaceuticals, Inc.: net property, plant and equipment
Net property, plant and equipment for Citius Pharmaceuticals, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Citius Pharmaceuticals, Inc. financial histories
What this measure means
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
Exact concept: us-gaap:PropertyPlantAndEquipmentNet. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2016-09-30 to 2023-09-30. The SEC response was captured on 2026-09-20.
This selected history ends more than two years before capture. Do not treat its final value as a current balance or current annual result. More recent filings may use another accounting tag; inspect the filings before drawing conclusions about the company.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2023-09-30 | 1,432 | USD | 2024-12-27 | 10-K · 0001213900-24-113149 |
| At date | 2022-09-30 | 4,100 | USD | 2023-12-29 | 10-K · 0001213900-23-099889 |
| At date | 2021-09-30 | 7,023 | USD | 2022-12-22 | 10-K · 0001213900-22-082217 |
| At date | 2020-09-30 | 1,577 | USD | 2021-12-15 | 10-K · 0001213900-21-065464 |
| At date | 2019-09-30 | 590 | USD | 2020-12-16 | 10-K · 0001213900-20-043004 |
| At date | 2018-09-30 | 1,483 | USD | 2019-12-16 | 10-K · 0001213900-19-026259 |
| At date | 2017-09-30 | 3,236 | USD | 2018-12-11 | 10-K · 0001213900-18-017214 |
| At date | 2016-09-30 | 3,742 | USD | 2017-12-13 | 10-K · 0001213900-17-013191 |
Related financial histories
- Citius Pharmaceuticals, Inc.: total assets
- Citius Pharmaceuticals, Inc.: total liabilities
- Citius Pharmaceuticals, Inc.: stockholders equity
- Citius Pharmaceuticals, Inc.: cash and cash equivalents
- Citius Pharmaceuticals, Inc.: net income or loss
- Citius Pharmaceuticals, Inc.: operating cash flow
- Citius Pharmaceuticals, Inc.: capital expenditure payments
- Citius Pharmaceuticals, Inc.: revenue
- Citius Pharmaceuticals, Inc.: financing cash flow
- Citius Pharmaceuticals, Inc.: investing cash flow
- Citius Pharmaceuticals, Inc.: retained earnings or deficit
- Citius Pharmaceuticals, Inc.: basic weighted-average shares
- Citius Pharmaceuticals, Inc.: diluted weighted-average shares
- Citius Pharmaceuticals, Inc.: basic earnings per share
- Citius Pharmaceuticals, Inc.: diluted earnings per share
- Citius Pharmaceuticals, Inc.: income tax expense or benefit
- Citius Pharmaceuticals, Inc.: share-based compensation expense
- Citius Pharmaceuticals, Inc.: operating income or loss
- Citius Pharmaceuticals, Inc.: current assets
- Citius Pharmaceuticals, Inc.: interest expense
- Citius Pharmaceuticals, Inc.: current liabilities
- Citius Pharmaceuticals, Inc.: current accounts payable
- Citius Pharmaceuticals, Inc.: goodwill carrying amount
- Citius Pharmaceuticals, Inc.: operating expenses
- Citius Pharmaceuticals, Inc.: research and development expense
Inspect the source
- Entity
- Citius Pharmaceuticals, Inc. / CIK 0001506251
- Captured
- 2026-09-20T09:12:24.553Z
- SEC response SHA-256
dab437b1abcb106ce657672edecf4aab637b5713b2c1870820e246433043b176
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001506251.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))